AbbVie won the latest testosterone side effects lawsuit alleging its testosterone replacement therapy AndroGel caused a man to suffer debilitating blood clots, but the two previous plaintiffs wins with verdicts totaling nearly $300 million suggest the fight has only just begun. AbbVie’s AndroGel has enjoyed the lion’s share of sales in the once-booming testosterone replacement therapy market. The hormone treatment was approved by the Food and Drug Administration (FDA) in 2000 for the treatment of hypogonadism, a condition in which there is a testosterone deficiency due to a genetic defect, illness or trauma. But AbbVie began aggressively promoting the drug ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.